The week in 60 seconds
What happened, and nothing elseThe market stopped paying for good news.
- Estee Lauder raised guidance and rose 16.30 percent; Walmart raised guidance and fell 9.15 percent.
- Energy beat Technology by 8.43 percentage points, the widest sector gap of any issue so far.
- The Fed published minutes showing three officials wanted a rate increase, and the ten year Treasury yield rose with them.
- Moderna rose 176.97 percent in a single session on the first Phase 3 win for an mRNA cancer vaccine.
- Core PCE inflation and NVIDIA's results both land on August 26 and will test whether the rotation holds.
You have the headline. The brief adds the market setup behind it, a line on each of the five, and what matters next. Continue to the 5-minute brief →
The 5-minute brief
~4 minMarket read
Measured from the August 13 close through Thursday, August 20, the S&P 500 ETF fell 1.96 percent and the equal weight version of the same index fell 1.10 percent, a fourth straight down week. Only two of eleven sectors finished positive. On August 19 the Federal Reserve published the minutes of its July meeting, which recorded a 9 to 3 vote to hold with three officials preferring a quarter point increase, and stated that many participants assessed that policy tightening would likely be necessary if inflation did not decline. The same morning Merck and Moderna said their personalised mRNA cancer vaccine met both endpoints in a Phase 3 melanoma trial, the first late stage success for the approach, and Moderna rose 176.97 percent in a session. On August 20 Walmart raised every line of its full year outlook and fell 9.15 percent anyway. Brent crude rose 7.71 percent to $93.78 with the Strait of Hormuz still contested, gold rose 3.50 percent to $4,516.30, and the dollar index fell 1.12 percent. Technology finished last of the eleven sectors at negative 4.02 percent.
Market Risk Score: 63 / 100 (Elevated).
The risk score grades overall market conditions from 0 (calm) to 100 (high risk). It sets how cautious the week's read is. It is not a signal to buy or sell anything.
The five
- 01MRNA, view score cardModerna, Inc.Cancer vaccine readoutWeekly moveup 109.5 percent
This is the first time an mRNA cancer treatment has met a Phase 3 endpoint, and it is the reason Health Care rose 3.51 percent on August 19 alone, which is the whole of the sector gain for the week.
- 02MRVL, view score cardMarvell Technology, Inc.Google custom siliconWeekly moveup 13.0 percent
Technology was the worst sector of the week at negative 4.02 percent and Marvell rose 12.98 percent inside it, including 5.79 percent on August 20 while the Nasdaq 100 fell 0.72 percent.
- 03EL, view score cardThe Estee Lauder Companies Inc.Margin turnWeekly moveup 10.1 percent
Consumer Staples fell 0.79 percent as a sector, so none of this was a defensive bid.
- 04TNK, view score cardTeekay Tankers Ltd.Hormuz freight shockWeekly moveup 9.1 percent
This is the same shock that led the last issue, expressed through the link in the chain that actually gets paid for it.
- 05STLD, view score cardSteel Dynamics, Inc.Tariff repricingWeekly movedown 15.9 percent
It is the largest decline in the screen and the clearest example of what this week was actually about.
Weekly move is each stock's movement during the window this issue analyzes (Week of August 13 to August 20, 2026), which closes before the issue publishes. It is not a return earned after publication. How each figure is measured →
What matters next
- Aug 21. The reported deadline in the United States and Canada steel and aluminium tariff talks
- Aug 25. Conference Board consumer confidence index
- Aug 26. The second estimate of second quarter GDP and the core PCE price index
You have the briefing.
Full research adds:
- the evidence behind the market read, and what would break it
- the complete case and the bear case on all five
- the next dated event for each name, and what result confirms or ends the thesis
- the primary sources every claim rests on
- the calls this issue is willing to be graded on next week
Full research
~17 minWeek ahead: the full analysis
I expect the cost side to keep setting direction into Jackson Hole. Over the coming week I expect Energy to keep beating Technology. The Hormuz disruption has no diplomatic path back to normal, and the Fed has just published minutes saying tightening would likely be necessary if inflation does not fall, so this is a supply shock the central bank cannot cut into. That combination is a headwind for long duration multiples and a tailwind for the assets that price the shortage. I put it at 62 percent, which is moderate confidence, and it is deliberately lower than it feels. My own record on one week sector calls is 3 correct out of 16, and I would rather publish that number than quietly ignore it.
What would prove me wrong. Technology beats Energy by more than 2.0 percentage points between the August 24 close and the August 28 close, measured on the sector funds XLK and XLE. I put the odds of this view holding at 62%.
- Aug 21. The reported deadline in the United States and Canada steel and aluminium tariff talks
Settles the Steel Dynamics pick in this issue in one direction or the other, on the day it is delivered - Aug 25. Conference Board consumer confidence index
The first read on the consumer after the two largest US retailers both sold off on results in the same week - Aug 26. The second estimate of second quarter GDP and the core PCE price index
The first inflation print since the minutes revealed three officials wanted a rate increase, and the number that decides whether that debate gets louder - Aug 26. NVIDIA second quarter results after the close
The AI infrastructure complex fell hard this week on rates rather than on demand, and this is where demand actually gets checked - Aug 27. Marvell second quarter fiscal 2027 results
The Stock of the Week reports four sessions after this issue, against a consensus of roughly $2.71 billion of revenue - Aug 28. Kevin Warsh delivers his first Jackson Hole keynote as Fed Chair, expected Friday morning
The Kansas City Fed had not published the agenda at the time of writing, and Jackson Hole is historically where the Fed signals a change of direction before it makes one
The biggest risk right now. A United States and Iran de-escalation reopens the Strait of Hormuz, and crude, tanker rates and the whole energy bid unwind in a single session. Brent rose 7.71 percent to $93.78 this week and Gulf to China tanker earnings are above $520,000 a day against a normal $20,000 to $60,000. Lloyds List Intelligence reported on August 19 that United States and Iran diplomacy has effectively collapsed, which is precisely why the rate is where it is. A price built on the absence of a deal does not need a deal to fall, only a credible sign that one is coming. Brent crude settling below $80 a barrel on or before September 4, 2026. I put it at 25% by September 4, 2026.
Last week I said, and I was right
That the broadening would hold, and the equal weight S&P 500 would keep pace with or beat the cap weighted index between the August 17 and August 21 closes. Measured from the August 17 close to the August 20 close, the last close available before this issue went out, the equal weight index fell 0.23 percent while the cap weighted index fell 1.30 percent, so the average stock beat the index by 1.07 points. Four of the five watch list items also resolved the way I said. The July minutes showed three officials wanting a hike, Walmart raised rather than cut its full year sales outlook, Brent held above $80, and the equal weight index beat the Dow. The fifth, about NVIDIA, resolves on August 26. Not close, and on the right side. I said I would be wrong if the cap weighted index won by more than 1.2 points. It lost by 1.07 points instead, a margin of 0.77 sigma from the trigger. One graded call is not a record, though. The ledger needs eight before a survival rate means anything, which is why the watch list items matter more than the headline verdict right now.
This week's five
MRNA, view score card · Moderna, Inc. · Health Care / Biotechnology
- Friday Five Score
- 79 / 100
- Move before publication
- +109.5%
- Actionability
- News Spike
- Next date
- Nov 12
Merck and Moderna reported on August 19 that their personalised mRNA cancer vaccine met both endpoints in a Phase 3 melanoma trial, the first late stage success for the approach. The stock rose 176.97 percent that session and handed back 23.55 percent the next day. It is a genuine scientific result attached to a company that lost $2.1 billion in the first half of this year and has no approval, no filing date and no named venue for the full data.
The catalyst. On August 19 Merck and Moderna announced that the Phase 3 INTerpath-001 trial of intismeran autogene combined with KEYTRUDA met its primary endpoint of recurrence free survival and its key secondary endpoint of distant metastasis free survival, in 1,137 patients with completely resected stage IIB to IV melanoma, with no new safety signals. The stock rose 176.97 percent that session and fell 23.55 percent the next. Merck & Co., Inc., August 19, 2026
Why it made the five. This is the first time an mRNA cancer treatment has met a Phase 3 endpoint, and it is the reason Health Care rose 3.51 percent on August 19 alone, which is the whole of the sector gain for the week. Nothing else in the screen was a scientific result rather than a business result, and nothing else came close on size.
What to watch next. Nov 12: Moderna analyst day, the next scheduled company event. It matters mostly because of what has no date: the companies have named neither a meeting for the full INTerpath-001 data nor a regulatory filing target. Confirms the thesis: A named filing timeline, or full data showing a benefit in line with the 49 percent reduction in recurrence risk seen in the earlier Phase 2b study. Breaks it: Months passing with no meeting, no submission and no detail beyond the August 19 headline.
The case against it. There is no approved product, no filing date and no named meeting for the full data. Moderna reported $534 million of revenue in the first half of 2026 against a $2.1 billion loss over the same six months, and used $1.2 billion of cash running the business. It held $6.9 billion of cash and investments at the end of June, before paying a $950 million litigation settlement in July. And going into the readout, 49.8 million shares were sold short, roughly one share in eight and more than ten days of average trading volume, so a real part of that 176.97 percent day was forced covering rather than new conviction. The 23.55 percent give back the next morning is what that looks like.
Weekly move (before publication): +109.5%
Every MRNA appearance →Track this pick on the Scoreboard →Size a position in it →
MRVL, view score card · Marvell Technology, Inc. · Technology / Semiconductors
- Move before publication
- +13.0%
- Next date
- Aug 27
An 8-K on August 19 disclosed a custom silicon agreement with Google and a warrant letting Google acquire up to 58,970,907 shares at $206.58. Almost all of it vests only as Google actually buys chips, one step for every $500 million of custom product revenue. The stock rose while its sector had its worst week of the year, and it reports on August 27.
The catalyst. An 8-K filed August 19 disclosed that Marvell and Google entered a commercial agreement on July 29 covering custom silicon across the TPU ecosystem, and that on August 18 Marvell issued Google a warrant to acquire up to 58,970,907 shares at $206.58. Only 1,360,867 of those vest on time. The rest vest in 240 equal steps, one for every $500 million of custom product revenue through fiscal 2033. The stock rose 9.85 percent on the filing day and 5.79 percent the day after. U.S. Securities and Exchange Commission, August 19, 2026
Why it made the five. Technology was the worst sector of the week at negative 4.02 percent and Marvell rose 12.98 percent inside it, including 5.79 percent on August 20 while the Nasdaq 100 fell 0.72 percent. The vesting schedule is the part worth reading twice. Google only gets the shares if it buys the chips, so a customer has tied its own claim on the equity to roughly $120 billion of purchases it has not made yet.
What to watch next. Aug 27: Second quarter fiscal 2027 results at 1:45 p.m. Pacific time, and the first management commentary on the Google agreement. Confirms the thesis: Revenue at or above the roughly $2.71 billion consensus, with management putting a number on custom product revenue under the agreement. Breaks it: A revenue miss, or management declining to size the Google business at all, which would leave the warrant as the only evidence there is.
The case against it. The warrant is about 6.7 percent of the shares outstanding, and dilution is dilution however it is earned. Google fixed its price at $206.58 on August 18 and the stock closed the week at $251.01, so that claim is already roughly 18 percent in the money before a single chip has been delivered under the agreement. The stock has risen 252 percent over 52 weeks against 20 percent for the index, so the market was paying for this franchise long before the filing landed. And all of it gets marked to a number on August 27, four sessions after this issue arrives, when Marvell reports against a consensus of about $2.71 billion of revenue.
Weekly move (before publication): +13.0%
Every MRVL appearance →Track this pick on the Scoreboard →Size a position in it →
EL, view score card · The Estee Lauder Companies Inc. · Consumer Staples / Beauty
- Move before publication
- +10.1%
- Next date
- Nov 2
Estee Lauder reported fiscal 2026 results on August 19 and guided fiscal 2027 adjusted earnings to $3.10 to $3.35 a share with an adjusted operating margin of 12.7 to 13.5 percent against 11.2 percent delivered. The stock rose 16.30 percent that day while its sector fell on the week. It is the one name in this issue whose improvement is about costs it controls rather than about a headline.
The catalyst. Fiscal 2026 results on the morning of August 19: fourth quarter net sales up 6 percent as reported and 5 percent organic, adjusted earnings of $0.39 a share against a $0.32 estimate on revenue of $3.63 billion against $3.55 billion expected, and full year organic sales up 3 percent. The fiscal 2027 outlook guided adjusted earnings to $3.10 to $3.35 a share and adjusted operating margin to 12.7 to 13.5 percent. The stock rose 16.30 percent that session. The Estee Lauder Companies Inc., August 19, 2026
Why it made the five. Consumer Staples fell 0.79 percent as a sector, so none of this was a defensive bid. It is also the only pick of the five that has trailed the market over the past year, up 11.07 percent against 19.51 percent for the S&P 500 ETF, which means the re-rating starts from a low base rather than extending a run. The improvement is in margin, and margin is the part a management team actually controls.
What to watch next. Nov 2: First quarter fiscal 2027 results at 8:30 a.m. Eastern time, the first quarter measured against the new margin guide. Confirms the thesis: Operating margin tracking inside the 12.7 to 13.5 percent range with organic sales inside the 3 to 5 percent guide. Breaks it: Margin below last year, or a cut in the first quarter of the year the guide was just raised for.
The case against it. The guide the company just gave is $3.10 to $3.35 a share for fiscal 2027. At Thursday close of $96.15 the stock is already about 30 times the middle of that, so the price pays in full for a margin recovery that has not happened yet. That leaves the guide itself as the whole of the thesis and gives a miss nowhere to hide. It is also worth remembering that a 16 percent day does not undo a bad year: even after this week the stock has trailed the index over 52 weeks.
Weekly move (before publication): +10.1%
Every EL appearance →Track this pick on the Scoreboard →Size a position in it →
TNK, view score card · Teekay Tankers Ltd. · Energy / Marine Shipping
- Move before publication
- +9.1%
Tanker earnings on the Gulf to China route were above $520,000 a day on August 19, against a normal range of $20,000 to $60,000, with Hormuz transits down to 73 from 91 a week earlier. Teekay ended the second quarter with more than $1.2 billion of cash and earned $5.56 a share in that quarter alone, against a $91.12 close. None of this is a company story, and it unwinds the day the strait reopens.
The catalyst. Lloyds List Intelligence reported on August 19 that earnings on the TD3C Middle East Gulf to China route were above $520,000 a day, against a normal range of roughly $20,000 to $60,000, with 73 Hormuz transits between August 10 and 16 against 91 the week before and no credible near term path to de-escalation. Brent crude rose 7.71 percent over the week to $93.78. Teekay rose on four of the five sessions. Lloyds List Intelligence, August 19, 2026
Why it made the five. This is the same shock that led the last issue, expressed through the link in the chain that actually gets paid for it. A refiner earns on a margin you have to infer. A tanker earns a rate that is published daily, and that rate is currently around ten times normal. Integrated oil companies rose 4 to 5 percent on the week and Teekay rose 9.07 percent, which is the difference between owning the commodity and owning the bottleneck.
What to watch next. The Gulf to China freight rate, which settles daily and is close to a live reading of the company revenue line. There is no scheduled Teekay event before third quarter results and the company has not published that date. Confirms the thesis: Route earnings holding above $300,000 a day and Hormuz transits staying below 90 a week. Breaks it: A credible de-escalation headline. Rates at this level fall faster than they rose.
The case against it. There was no Teekay disclosure inside the measurement window at all, so this is a macro catalyst and not a company one, and it reverses on a headline rather than on a business. The market already knows. Teekay earned $5.56 a share of adjusted profit in the second quarter alone and the stock closed at $91.12, so annualising that one quarter puts it at roughly four times earnings. A market that believed the rate would persist would not price it that way. It is also the smallest name here at about $30.5 million of trading a day, roughly one hundredth of Marvell, so it does not absorb size the way the others do.
Weekly move (before publication): +9.1%
Every TNK appearance →Track this pick on the Scoreboard →Size a position in it →
STLD, view score card · Steel Dynamics, Inc. · Materials / Steel
- Move before publication
- -15.9%
- Next date
- Aug 21
Steel Dynamics fell 15.94 percent on a report that United States tariffs on Canadian steel could be halved to 25 percent, with the reported deadline falling on the day this issue lands. Nothing about the company changed. What got repriced was how much of its earnings power the market thought was policy rather than business, and the answer turned out to be a lot.
The catalyst. On August 19 Bloomberg reported, citing people familiar with the matter, that a tentative United States and Canada trade deal could cut tariffs on certain Canadian steel and aluminium exports from 50 percent to 25 percent, with planned tariffs paused for three days ahead of a Friday deadline. Steel Dynamics fell 7.53 percent that day and 5.20 percent the next. Nucor fell 11.68 percent and Cleveland Cliffs fell 11.60 percent over the week. Yahoo Finance, August 19, 2026
Why it made the five. It is the largest decline in the screen and the clearest example of what this week was actually about. Nothing changed at Steel Dynamics. Revenue, mills, order book and management are exactly where they were on August 18. What was marked down was the value of a policy, and a 15.94 percent move in two sessions tells you how much of the last year of steel earnings the market believed was tariff rather than business.
What to watch next. Aug 21: The reported deadline in the United States and Canada steel and aluminium tariff talks. Confirms the thesis: A confirmed cut to 25 percent, which would prove the last two sessions were the market repricing policy rather than panicking. Breaks it: The talks collapse and the 50 percent rate stays, in which case the whole 15.94 percent decline was a headline the market got wrong.
The case against it. The case against buying the fall is that the fall may not be finished. The deal is a report, not an announcement, and the reported deadline is Friday, August 21, the day this issue reaches you, so the catalyst can settle either way within hours of you reading it. A confirmed cut takes more out of the price. A collapse in the talks puts it back. Neither outcome is a view about steel demand, which is why this name is in the issue as a lesson rather than as an idea.
Weekly move (before publication): -15.9%
Every STLD appearance →Track this pick on the Scoreboard →Size a position in it →
Stock of the week
Marvell Technology (MRVL, view score card)
Stock of the Week is the most instructive name in the issue, not the largest weekly mover.
Marvell is not the biggest gainer in this issue and that is rather the point. Moderna moved five times as far on a result that carries no approval, no filing date and no revenue. Marvell moved on a document. A customer signed an agreement, and then handed over a claim on about 6.7 percent of the company that only becomes real if that customer buys roughly $120 billion of chips over the next seven years. That is the unusual case where the disclosure and the incentive point in the same direction, and it happened in the week its own sector had its worst run of the year. The reason for caution is the same fact from the other side: almost none of it has been earned yet, and the first evidence either way arrives on August 27.
Sector rotation
Into: Energy · Health Care · Materials · Real Estate
Out of: Technology · Industrials · Financials · Communication Services
Rotation is money moving between industry groups. It shows where big investors added this week and where they pulled back.
Market context, not picks
Raised its outlook on August 20 and fell anyway. The counter-example that carries the quality-of-earnings argument in this issue.
Second quarter results land inside next week’s window and set the tone for the custom-silicon read.
These companies are named because they explain something about the week. They are not Friday Five selections, they carry no rank, and they are not tracked on the Scoreboard.
Terms in this issue
Quality of Earnings. How much of a reported profit comes from a company’s ordinary operations rather than from one off items such as a refund or an asset sale. Two companies can report the same beat and be worth very different things. More in the Learn hub →
Section 232 tariff. A United States import tax imposed on national security grounds rather than through a trade dispute. Because the executive branch sets it, it can be raised or cut without Congress, which makes it faster to change than most trade rules.
Warrant. A contract that lets the holder acquire shares from the company at a fixed price for a set period. Exercising one creates new shares rather than moving existing ones, so everyone else ends up owning a slightly smaller slice.
Recurrence free survival. In a cancer trial, how long patients go after treatment before the disease returns or they die. It is the main measure used when a tumour has already been removed and the question is whether it stays gone.
Equal weight index. A version of an index that counts every company the same, so the smallest counts as much as the largest. Comparing it with the normal version shows whether a move was broad or came from a handful of giants.
Freight rate. What a shipowner is paid per day to carry cargo on a given route. It is quoted publicly and settles daily, so for a tanker company it is close to a live reading of revenue.